黄连素伍用谷维素对Ⅱ型糖尿病患者肠道菌群的影响

目的探讨黄连素伍用谷维素对Ⅱ型糖尿病患者肠道菌群的影响。方法研究对象为130例Ⅱ型糖尿病患者,其中未服用黄连素及谷维素治疗的患者47例,服用黄连素伍用谷维素治疗的患者43例,仅服用谷维素的患者40例。观察三组患者的临床表现、粪便外观性状,并采用直接涂片革兰染色法镜检各组粪便的菌落数及球杆比。结果未治疗组粪便菌落数和球杆比分别为(59 560±855)和(1.03±0.4);黄连素伍用谷维素治疗组粪便菌落数和球杆比分别为(60 490±919)和(1.04±0.5);谷维素治疗组粪便菌落数和球杆比分别为(59 211±155)和(1.03±0.2)。后两组与第一组(对照组)相比菌落数与球杆比均无明显差异(P0.05)。大便的物理性状三者亦无明显差异。临床观察黄连素伍用谷维素组偶见一过性大便次数增多、腹胀,均未作处理自愈,未见发热。结论黄连素伍用谷维素对Ⅱ型糖尿病患者肠道菌群无显著性影响。

Preliminary investigation of the effect of berberine-oryzanol on intestinal mircoflora in the type Ⅱ diabetes

Objective To investigate the effect of berberine-oryzanol on intestinal mircoflora in type Ⅱ diabetes.Methods We studied 130 type Ⅱ diabetes patients,which were divided into three groups：the untreated group（47 cases）,the berberine-oryzanol treated group（43 cases）and oryzanol treated group（40 cases）.The clinical manifestations and feces morphology of three groups were observed.All feces samples were performed direct smear and Gram staining to caculate their bacteria colonies and C/B value.Results The respective bacteria colonies and C/B value of three groups were 59 560±855 and 1.03±0.4,60 490±919 and 1.04±0.5,59 211±155 and 1.03±0.2.There were no significant differences between the latter two groups and the first group（the control group）in the number of intestinal bacteria colonies and C/B value.Increasing frequency of defecation and abdominal distension were observed occasionally in some berberine-oryzanol treated cases,which was relieved spontaneously without being treated,and no fever was observed in these cases.Conclusion Berberine-oryzanol had no significant effect on intestinal mircoflora of people with diabetes.